Altria Group, Inc. (MO) is one of the largest U.S. consumer staples companies, best known as the parent of Philip Morris USA and the maker of Marlboro cigarettes. It also owns a growing portfolio of smoke-free products, including the on! and on! PLUS oral nicotine pouches and the NJOY e-vapor brand. After a strong 2026 rally that has lifted shares roughly 30% year to date, the central question for investors is whether the stock can push to $85.
Because the analyst-derived mean does not meet the minimum threshold for a meaningful upside target, this article uses a fallback approach. The nine most recent, verifiable price targets from identifiable firms produce a low-to-high range of $58 to $82 and an arithmetic mean of roughly $71, which is below the latest close of $74.31. The highest published target, $82 from Bank of America Securities, is only about 10% above the current price, and the average of the above-price targets (Goldman Sachs at $77, Stifel at $77, UBS at $79, and Bank of America at $82) rounds to about $79, still under the 10% upside threshold.
In short, the sell-side has not priced in a move to $85. Bulls such as Goldman Sachs and UBS emphasize pricing power, smoke-free growth, and a robust dividend, while bears such as Barclays (which cut its target to $58 in August) argue that cigarette volume erosion and regulatory risk limit upside. The $85 figure used here instead reflects independent valuation models and investor research that publicly cite objectives in the mid-$80s, including model-based targets near $85 to $86 and bull-case estimates above that level.
As of late October 2026, MO trades near $74.31, just below its 52-week high of $77.06 and its all-time high of roughly $77.79. Reaching $85 would require a gain of about 14%, a substantial move that would also mean a decisive breakout to new record territory.
The path depends on fundamentals rather than multiple expansion alone. Altria has guided to full-year 2026 adjusted EPS of $5.56 to $5.72, roughly 4% growth at the midpoint, and reported a first-quarter beat with adjusted EPS of $1.32 versus a $1.25 consensus. With a forward P/E (price-to-earnings ratio) in the low teens, the stock trades at a discount to the broader market. For the shares to reach the mid-$80s, investors would likely need to see sustained smoke-free growth, stabilized cigarette economics, and at least modest multiple re-rating.
Several verified factors support the bull case. The on! and on! PLUS nicotine pouch franchise is scaling, and Altria has received U.S. FDA marketing authorization for additional pouch products. Marlboro's premium retail share has held near the 59% to 60% range, and management has said the migration between illicit flavored e-vapor and cigarettes is moderating, which has slowed volume declines. The dividend, with a yield near 6%, remains a major attraction for income investors and has helped support the shares through recent market volatility. Analysts also expect normalized EPS to keep rising at a mid-single-digit pace.
The principal obstacle is structural: cigarette volumes are in long-term decline, and the smokeable segment still generates the large majority of Altria's revenue and operating income. Marlboro's retail share has eroded from above 43% in 2019 to roughly 40%, reflecting category shrinkage and competitive pressure. Regulatory risk is persistent, including the FDA's posture on e-vapor and nicotine pouch authorizations and enforcement. Litigation and tax policy changes also remain overhangs. A stock that already trades near record highs leaves less margin for error if smoke-free growth disappoints or if the broader "value and dividend" rotation loses steam.
Technically, the stock has been in a strong uptrend, trading above its 50-day and 200-day moving averages, which sat near $69.50 and $68.50 respectively in late October. The $77 area, marking the 52-week and all-time highs, is the first meaningful resistance zone. Beyond that, a move toward $85 would require clearing what is effectively uncharted territory. On the downside, the $70 to $71 zone and the $65 to $67 range represent visible support areas where buyers have previously stepped in.
Analyst price targets typically reflect a roughly 12-month horizon, though the $85 objective referenced here draws from model-based research with a multi-year view. Investors should watch upcoming quarterly results and guidance updates, particularly any revision to the 2026 EPS outlook, as well as smoke-free shipment and share data for on! and NJOY. Regulatory developments, including FDA decisions on nicotine products, litigation outcomes, and interest-rate signals that affect yield-oriented equities, are also likely to shape the stock's trajectory. None of these factors provides a guarantee about the direction of the share price.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the signals to discover new opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. For investors following a large-cap name like MO, this kind of automated, data-driven monitoring can complement fundamental research by flagging changes in momentum and market structure as they develop.
The $85 level is not the average Wall Street price target; it is a publicly discussed objective grounded in independent valuation models and investor commentary, reflecting a case where the sell-side consensus, near $71, trails the market price. Reaching $85 would require a gain of about 14% and a breakout to new all-time highs. Supportive factors include a high dividend yield, scaling nicotine-pouch brands, Marlboro's share stabilization, and mid-single-digit EPS growth. The counterweights are persistent cigarette volume declines, regulatory and litigation risk, and a valuation tied to a structurally shrinking category. The wide $58-to-$82 analyst range underscores genuine disagreement, and investors should monitor earnings, guidance, smoke-free momentum, and regulatory news rather than assume any particular price outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MO has been loosely correlated with PM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MO jumps, then PM could also see price increases.